Full Archive
Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report
Cancer Treatment and Research Communications 2021 February 24 [Link] Xiaomin Niu, Chenglei Zhou, Aiyan Hu, Lingzi Su, Dan Lin, Hui Han, Yan Lu Abstract Synchronous malignant mesothelioma (MM) and lung carcinoma are extremely rare in patients without a history of asbestos exposure and poses tremendous difficulties in clinical management. We report a patient without asbestos…
Read MorePatients and family caregivers report high treatment expectations during palliative chemotherapy: a longitudinal prospective study
BMC Palliative Care 2021 February 26 [Link] Tine Ikander, Stefan Starup Jeppesen, Olfred Hansen, Mette Raunkiær, Karin Brochstedt Dieperink Abstract Background: When discussing treatment options and future care, it is important to understand the expectations of patients and family caregivers related to palliative chemotherapy and to identify patterns in patients’ quality of life. The study…
Read MoreEliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
Molecular Therapy Oncolytics 2021 January 21 [Link] Zhiwu Tan, Mei Sum Chiu, Chi Wing Yan, Kwan Man, Zhiwei Chen Abstract The potency of cancer vaccines is often compromised by a variety of immunoinhibitory mechanisms, including stimulation of the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint pathway. Here, to overcome inhibition,…
Read MoreOutcomes of Conversion to Extrapleural Pneumonectomy from Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Seminars in Thoracic and Cardiovascular Surgery 2021 February 17 [Link] Akifumi Nakamura, Masaki Hashimoto, Seiji Matsumoto, Nobuyuki Kondo, Takashi Kijima, Seiki Hasegawa Abstract In recent years, there has been a shift from extrapleural pneumonectomy (EPP) toward pleurectomy/decortication (P/D) as the preferred surgical technique. However, we occasionally encounter difficult cases wherein visceral pleurectomy requires conversion to…
Read MoreOutcomes of Conversion to Extrapleural Pneumonectomy from Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Seminars in Thoracic and Cardiovascular Surgery 2021 February 17 [Link] Akifumi Nakamura, Masaki Hashimoto, Seiji Matsumoto, Nobuyuki Kondo, Takashi Kijima, Seiki Hasegawa Abstract In recent years, there has been a shift from extrapleural pneumonectomy (EPP) toward pleurectomy/decortication (P/D) as the preferred surgical technique. However, we occasionally encounter difficult cases wherein visceral pleurectomy requires conversion to…
Read MoreGATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis
Virchows Archiv 2021 February 11 [Link] Zheng Hua Piao, Xin Cheng Zhou, Jia Yi Chen Abstract Sarcomatoid malignant mesothelioma (SMM) tends to occur in the pleura and is morphologically similar to lung sarcomatoid carcinoma (LSC) and organizing pleuritis (OP). Because SMM often does not express mesothelial markers, it is very difficult to distinguish from LSC…
Read MoreSyndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
Cancers 2021 February 6 [Link] Joman Javadi, Ghazal Heidari-Hamedani, Angelika Schmalzl, Tünde Szatmári, Muzaffer Metintas, Pontus Aspenström, Anders Hjerpe, Katalin Dobra Abstract Malignant mesothelioma (MM) is an aggressive tumor of the serosal cavities. Angiogenesis is important for mesothelioma progression, but so far, anti-angiogenic agents have not improved patient survival. Our hypothesis is that better understanding…
Read MoreEnhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models
Cancer Immunology, Immunotherapy 2021 February 8 [Link] Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto, Koji Tamada Abstract Chimeric antigen receptor (CAR)-T cell therapy has impressive efficacy in hematological malignancies, but its application in solid tumors remains a challenge. Multiple hurdles associated with the biological and immunological features of solid tumors…
Read MoreSerum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…
Read MorePotential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma
Oncology Letters 2021 February [Link] Vincenzo Fontana, Maria Pia Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Paolo Dessanti, Silvio Roncella Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting…
Read More